Pharmacotherapy of myopic choroidal neovascularization

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients. Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents. Results: At this time, anti-VEGF therapy agents are the first-line therapy in these patients. Comparative trials have not identified any major differences in treatment outcomes between aflibercept, bevacizumab, and ranibizumab. Only ranibizumab is approved for this indication in the US. Best visual outcomes are associated with younger age, smaller lesion size, and absence of chorioretinal atrophy. Conclusion: Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.

Original languageEnglish (US)
Pages (from-to)4853-4859
Number of pages7
JournalCurrent Pharmaceutical Design
Volume24
Issue number41
DOIs
StatePublished - Jan 1 2018

Fingerprint

Choroidal Neovascularization
Drug Therapy
Vascular Endothelial Growth Factor A
Therapeutics
Myopia
Atrophy
Pharmacology

Keywords

  • Aflibercept
  • Anti-vegf
  • Bevacizumab
  • Myopic choroidal neovascularization
  • Pegaptanib
  • Pharmacotherapy
  • Photodynamic therapy
  • Ranibizumab
  • Verteporfin

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Pharmacotherapy of myopic choroidal neovascularization. / Isildak, Hacer; Schwartz, Stephen; Flynn, Harry W.

In: Current Pharmaceutical Design, Vol. 24, No. 41, 01.01.2018, p. 4853-4859.

Research output: Contribution to journalArticle

@article{c7383a98c2a5450da3c8527ece52c660,
title = "Pharmacotherapy of myopic choroidal neovascularization",
abstract = "Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients. Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents. Results: At this time, anti-VEGF therapy agents are the first-line therapy in these patients. Comparative trials have not identified any major differences in treatment outcomes between aflibercept, bevacizumab, and ranibizumab. Only ranibizumab is approved for this indication in the US. Best visual outcomes are associated with younger age, smaller lesion size, and absence of chorioretinal atrophy. Conclusion: Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.",
keywords = "Aflibercept, Anti-vegf, Bevacizumab, Myopic choroidal neovascularization, Pegaptanib, Pharmacotherapy, Photodynamic therapy, Ranibizumab, Verteporfin",
author = "Hacer Isildak and Stephen Schwartz and Flynn, {Harry W}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1381612825666190124102641",
language = "English (US)",
volume = "24",
pages = "4853--4859",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "41",

}

TY - JOUR

T1 - Pharmacotherapy of myopic choroidal neovascularization

AU - Isildak, Hacer

AU - Schwartz, Stephen

AU - Flynn, Harry W

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients. Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents. Results: At this time, anti-VEGF therapy agents are the first-line therapy in these patients. Comparative trials have not identified any major differences in treatment outcomes between aflibercept, bevacizumab, and ranibizumab. Only ranibizumab is approved for this indication in the US. Best visual outcomes are associated with younger age, smaller lesion size, and absence of chorioretinal atrophy. Conclusion: Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.

AB - Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients. Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents. Results: At this time, anti-VEGF therapy agents are the first-line therapy in these patients. Comparative trials have not identified any major differences in treatment outcomes between aflibercept, bevacizumab, and ranibizumab. Only ranibizumab is approved for this indication in the US. Best visual outcomes are associated with younger age, smaller lesion size, and absence of chorioretinal atrophy. Conclusion: Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.

KW - Aflibercept

KW - Anti-vegf

KW - Bevacizumab

KW - Myopic choroidal neovascularization

KW - Pegaptanib

KW - Pharmacotherapy

KW - Photodynamic therapy

KW - Ranibizumab

KW - Verteporfin

UR - http://www.scopus.com/inward/record.url?scp=85064277245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064277245&partnerID=8YFLogxK

U2 - 10.2174/1381612825666190124102641

DO - 10.2174/1381612825666190124102641

M3 - Article

VL - 24

SP - 4853

EP - 4859

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 41

ER -